Lung Disease News |
FDA Rejects GSK's Breo Ellipta Asthma Therapy Use in Adolescents; Adult Use …
Lung Disease News GSK Incruse Ellipta COPD The U.S. Food and Drug Administration (FDA) ruled against the use of GlaxoSmithKline's new drug combination Breo Ellipta in asthma patients between the ages of 12 and 17. However, the Pulmonary-Allergy Drugs Advisory … |
View full post on asthma – Google News